Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

Journal: Journal of Clinical Investigation

Published: 2020-02-03

DOI: 10.1172/jci126896

Affiliations: 24

Authors: 26

Go to article
Institutions Share
Institut de Recherche en Cancérologie de Montpellier (IRCM), France 0.23
Cancer Institute of Montpellier (ICM), France 0.23
BioCampus Montpellier, France 0.08
Roche Deutschland Holding GmbH, Germany 0.04
Centre de Recherche en Cancérologie de Toulouse (CRCT), France 0.04
Université Toulouse III - Paul Sabatier (UPS), France 0.04
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA) 0.04
Department of Biological Regulation, WIS, Israel 0.04
Department of Discovery Oncology, Genentech, Inc., United States of America (USA) 0.04
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), France 0.03
Center for Physiology and Pharmacology (CPP), MUW, Austria 0.03
Comprehensive Cancer Center Vienna (CCC), Austria 0.03
Hôpital Arnaud de Villeneuve, CHU de Montpellier, France 0.03
Instituto de Investigación Hospital 12 de Octubre (i+12), Spain 0.02
University of Paris-Sud (UPSud), France 0.02
Department of Drug Development (DITEP), IGR, France 0.02
Faculty of Medicine, UCM, Spain 0.01
Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Austria 0.01
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 0.01
Hôpital Larrey, CHU-Toulouse, France 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER